Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

ENPP1 enzyme replacement therapy improves blood pressure and cardiovascular function in a mouse model of generalized arterial calcification of infancy.

Khan T, Sinkevicius KW, Vong S, Avakian A, Leavitt MC, Malanson H, Marozsan A, Askew KL.

Dis Model Mech. 2018 Oct 8;11(10). pii: dmm035691. doi: 10.1242/dmm.035691.

2.

Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action.

Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, Bouchard K, Andrien B, Marozsan A, Wang Y, Tamburini P.

PLoS One. 2018 Apr 12;13(4):e0195909. doi: 10.1371/journal.pone.0195909. eCollection 2018.

3.

Targeting Complement Pathways During Cold Ischemia and Reperfusion Prevents Delayed Graft Function.

Yu ZX, Qi S, Lasaro MA, Bouchard K, Dow C, Moore K, Wu Z, Barama A, Xu J, Johnson K, Marozsan AJ, Wang Y.

Am J Transplant. 2016 Sep;16(9):2589-97. doi: 10.1111/ajt.13797. Epub 2016 Apr 8.

4.

Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.

Ruseva MM, Peng T, Lasaro MA, Bouchard K, Liu-Chen S, Sun F, Yu ZX, Marozsan A, Wang Y, Pickering MC.

J Am Soc Nephrol. 2016 Feb;27(2):405-16. doi: 10.1681/ASN.2014121195. Epub 2015 Jun 5.

5.

Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies.

Chung NP, Matthews K, Kim HJ, Ketas TJ, Golabek M, de Los Reyes K, Korzun J, Yasmeen A, Sanders RW, Klasse PJ, Wilson IA, Ward AB, Marozsan AJ, Moore JP, Cupo A.

Retrovirology. 2014 Apr 25;11:33. doi: 10.1186/1742-4690-11-33.

6.

Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.

Klasse PJ, Depetris RS, Pejchal R, Julien JP, Khayat R, Lee JH, Marozsan AJ, Cupo A, Cocco N, Korzun J, Yasmeen A, Ward AB, Wilson IA, Sanders RW, Moore JP.

J Virol. 2013 Sep;87(17):9873-85. doi: 10.1128/JVI.01226-13. Epub 2013 Jul 3.

7.

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.

Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA.

Nat Struct Mol Biol. 2013 Jul;20(7):796-803. doi: 10.1038/nsmb.2594. Epub 2013 May 26.

8.

Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans.

Julien JP, Sok D, Khayat R, Lee JH, Doores KJ, Walker LM, Ramos A, Diwanji DC, Pejchal R, Cupo A, Katpally U, Depetris RS, Stanfield RL, McBride R, Marozsan AJ, Paulson JC, Sanders RW, Moore JP, Burton DR, Poignard P, Ward AB, Wilson IA.

PLoS Pathog. 2013;9(5):e1003342. doi: 10.1371/journal.ppat.1003342. Epub 2013 May 2.

9.

Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.

Lobritz MA, Ratcliff AN, Marozsan AJ, Dudley DM, Tilton JC, Arts EJ.

Antimicrob Agents Chemother. 2013 Jun;57(6):2640-50. doi: 10.1128/AAC.02511-12. Epub 2013 Mar 25.

10.

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Julien JP, Lee JH, Cupo A, Murin CD, Derking R, Hoffenberg S, Caulfield MJ, King CR, Marozsan AJ, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4351-6. doi: 10.1073/pnas.1217537110. Epub 2013 Feb 20.

11.

Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile.

Peterfreund GL, Vandivier LE, Sinha R, Marozsan AJ, Olson WC, Zhu J, Bushman FD.

PLoS One. 2012;7(10):e46966. doi: 10.1371/journal.pone.0046966. Epub 2012 Oct 10.

12.

Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.

Marozsan AJ, Ma D, Nagashima KA, Kennedy BJ, Kang YK, Arrigale RR, Donovan GP, Magargal WW, Maddon PJ, Olson WC.

J Infect Dis. 2012 Sep 1;206(5):706-13. doi: 10.1093/infdis/jis416. Epub 2012 Jun 25.

13.

Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.

Depetris RS, Julien JP, Khayat R, Lee JH, Pejchal R, Katpally U, Cocco N, Kachare M, Massi E, David KB, Cupo A, Marozsan AJ, Olson WC, Ward AB, Wilson IA, Sanders RW, Moore JP.

J Biol Chem. 2012 Jul 13;287(29):24239-54. doi: 10.1074/jbc.M112.371898. Epub 2012 May 29.

14.

A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.

Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA.

Science. 2011 Nov 25;334(6059):1097-103. doi: 10.1126/science.1213256. Epub 2011 Oct 13.

15.

Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures.

Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YK, Depetris R, Marozsan AJ, Sanders RW, Klasse PJ, Milne JL, Wilson IA, Olson WC, Moore JP, Subramaniam S.

Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11440-5. doi: 10.1073/pnas.1101414108. Epub 2011 Jun 27.

16.

Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.

Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42. doi: 10.1128/AAC.00086-10. Epub 2010 Jul 26.

17.

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

J Infect Dis. 2010 May 15;201(10):1481-7. doi: 10.1086/652190.

18.

Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss.

Anastassopoulou CG, Marozsan AJ, Matet A, Snyder AD, Arts EJ, Kuhmann SE, Moore JP.

PLoS Pathog. 2007 Jun;3(6):e79.

19.

Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity.

Lobritz MA, Marozsan AJ, Troyer RM, Arts EJ.

J Virol. 2007 Aug;81(15):8258-69. Epub 2007 May 23.

20.

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.

Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, Kuhmann SE.

Virology. 2007 Apr 25;361(1):212-28. Epub 2006 Dec 12.

21.

A yeast recombination-based cloning system to produce chimeric HIV-1 viruses and express HIV-1 genes.

Moore DM, Arts EJ, Gao Y, Marozsan AJ.

Methods Mol Biol. 2005;304:369-85.

PMID:
16061990
22.

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J, Moore JP.

Virology. 2005 Jul 20;338(1):182-99.

23.

Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.

Marozsan AJ, Moore DM, Lobritz MA, Fraundorf E, Abraha A, Reeves JD, Arts EJ.

J Virol. 2005 Jun;79(11):7121-34.

24.

Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen.

Baird HA, Marozsan AJ, Lederman MM, Landay A, Mildvan D, Kuritzkes DR, Kessler HA, Arts EJ.

AIDS Res Ther. 2005 Apr 12;2(1):2.

25.

Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates.

Marozsan AJ, Fraundorf E, Abraha A, Baird H, Moore D, Troyer R, Nankja I, Arts EJ.

J Virol. 2004 Oct;78(20):11130-41.

26.

Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses.

Wolinsky SM, Veazey RS, Kunstman KJ, Klasse PJ, Dufour J, Marozsan AJ, Springer MS, Moore JP.

Virology. 2004 Oct 10;328(1):19-29.

27.

The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.

Pugach P, Kuhmann SE, Taylor J, Marozsan AJ, Snyder A, Ketas T, Wolinsky SM, Korber BT, Moore JP.

Virology. 2004 Mar 30;321(1):8-22.

29.

Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C.

Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, Quiñones-Mateu ME, Penn-Nicholson A, Murray M, Richard N, Lobritz M, Zimmerman PA, Kawamura T, Blauvelt A, Arts EJ.

J Virol. 2003 Jan;77(2):1021-38.

30.

In vitro intersubtype recombinants of human immunodeficiency virus type 1: comparison to recent and circulating in vivo recombinant forms.

Quiñones-Mateu ME, Gao Y, Ball SC, Marozsan AJ, Abraha A, Arts EJ.

J Virol. 2002 Oct;76(19):9600-13.

31.

Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.

Marozsan AJ, Torre VS, Johnson M, Ball SC, Cross JV, Templeton DJ, Quiñones-Mateu ME, Offord RE, Arts EJ.

J Virol. 2001 Sep;75(18):8624-38.

32.

A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression.

Quiñones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, Vanham G, van Der Groen G, Colebunders RL, Arts EJ.

J Virol. 2000 Oct;74(19):9222-33.

33.

Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.

Torre VS, Marozsan AJ, Albright JL, Collins KR, Hartley O, Offord RE, Quiñones-Mateu ME, Arts EJ.

J Virol. 2000 May;74(10):4868-76.

Supplemental Content

Loading ...
Support Center